Evidence map›Paper›PMID 24894963›Full record

Trial reportAddiction (Abingdon, England)2014

Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use.

Keith G Heinzerling, Aimee-Noelle Swanson, Timothy M Hall, Yi Yi, Yingnian Wu, Steven J Shoptaw

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Addiction (Abingdon, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Bupropion and Naltrexone in Methamphetamine Use Disorder.The New England journal of medicine · 2021
    Trial
  9. Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Article
  17. Review
  18. Observational
  19. Methamphetamine Toxicities and Clinical Management.NEJM evidence · 2023 · on this map
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Keith G HeinzerlingUniversity of California Los Angeles (UCLA) Department of Family Medicine, UCLA Center for Behavioral and Addiction Medicine, Los Angeles, CA, USA.
Aimee-Noelle Swanson
Timothy M Hall
Yi Yi
Yingnian Wu
Steven J Shoptaw
University of California, Los Angeles · US

Funding

UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sung-Jae Lee · 1997 to 2026
$53.5M
UCLA Training Program on Addiction Medicine in Primary CareT32DA026400 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOPTAW, STEVEN J · 2009 to 2013
$1.3M
Pharmacogenomics and Medication Development for Methamphetamine DependenceK23DA023558 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HEINZERLING, KEITH GREGORY · 2008 to 2012
$848k
NIDA NIH HHS K23 DA023558NIDA NIH HHS T32 DA026400NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

aimsTwo previous randomized trials found an effect for bupropion in reducing methamphetamine use in the subgroup with lower frequency of methamphetamine use at baseline. This study aimed to replicate these results by comparing bupropion versus placebo in methamphetamine-dependent participants with less than daily methamphetamine use at baseline.

methodsMethamphetamine-dependent volunteers reporting methamphetamine use on ≤29 of past 30 days were randomized to bupropion 150 mg twice daily (n = 41) or placebo (n = 43) and out-patient counseling for 12 weeks. The primary outcome was the proportion achieving end-of-treatment (EOT) methamphetamine abstinence (weeks 11 and 12) for bupropion versus placebo. A post-hoc analysis compared EOT abstinence by medication adherence assessed via plasma bupropion/hydroxybupropion level.

resultsThere was no significant difference in EOT abstinence between bupropion (29%, 12 of 41) and placebo (14%, six of 43; P = 0.087). Among participants receiving bupropion, EOT abstinence was significantly higher in participants assessed as medication adherent by plasma bupropion/hydroxybupropion levels (54%, seven of 13) compared to non-adherent participants (18%, five of 28; P = 0.018). Medication adherence by plasma levels was low (32%).

conclusionsBupropion may be efficacious for reducing methamphetamine in people with less than daily baseline methamphetamine use, but the evidence remains inconclusive.

Indexed as

AdultAmphetamine-Related DisordersBupropionDopamine Uptake InhibitorsDrug MonitoringFemaleHumansMaleMethamphetamineMiddle AgedTreatment OutcomeBupropionDopamine Uptake InhibitorsMethamphetamineBupropionclinical trialmedication non-adherencemethamphetaminepharmacotherapyplacebo

Identifiers

PMID24894963
PMCPMC4192025
OpenAlexW1483496794

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.